Fairtility Ltd.

Fairtility Ltd. develops CHLOE, a transparent AI-powered decision support platform designed for reproductive medicine and IVF clinics. CHLOE provides explainable artificial intelligence that analyzes embryo quality, oocyte (egg) quality, lab performance metrics, and treatment progress. The platform monitors embryo development using biomarkers to deliver objective AI-driven assessment and ranking, removing subjectivity from embryo selection for transfer. For egg freezing and fertility preservation, CHLOE assesses oocyte potential from single images to support counseling and identify quality issues. The system automatically tracks lab performance KPIs to detect deviations early and support operational efficiency. CHLOE transforms complex laboratory data into clear visual insights, enabling transparent patient conversations from initial consultation through transfer while providing physicians real-time progress visibility without manual updates. The platform emphasizes transparent AI methodology, making clinical reasoning visible so embryologists and physicians can validate insights against their own expertise. CHLOE integrates securely across lab and clinic systems to streamline workflows, reduce manual data management, and improve clinic positioning. The company has partnerships with major academic medical centers and fertility clinics including Mayo Clinic, Memorial Sloan Kettering, Cleveland Clinic, Hadassah Medical Center, and Weill Cornell Medicine. Fairtility has received industry recognition including MedTech Breakthrough Awards.